Fintel reports that on October 10, 2025, Morgan Stanley maintained coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 18.17% Upside ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
If you're holding shares of Vertex Pharmaceuticals or thinking about adding some to your portfolio, you're not alone in ...
Treating pain has long been a challenge. Over-the-counter treatments often don’t do enough, while opioids block pain signals ...
A developer has filed plans to turn the former site of the radio station for Kiss 108 into a multifamily residential building ...
Vertex Pharmaceuticals has been a clear winner in the pharmaceutical sector. Over the past two decades, this powerhouse has ...
Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...
Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...
Zacks Investment Research on MSN
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback